Overlapping Spironolactone Dosing in Primary Aldosteronism and Resistant Essential Hypertension

Journal of Clinical Hypertension

Volumn 14, Issue 10, 2012, Pages 732-734

  Handler, Joel ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; NIFEDIPINE; POTASSIUM; SPIRONOLACTONE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; EDEMA; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HUMAN; HYPOKALEMIA; MALE; MONOTHERAPY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; DIURETICS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; POTASSIUM; SPIRONOLACTONE;

EID: 84867100855     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00693.x     Document Type: Article

References (18)

1. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
2. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertens. 2007;49:839-845.
3. Quinkler M, Stewart PM. Treatment of primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2010;24:923-932.
4. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary hyperaldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
5. Thakkar RB, Oparil S. Primary aldosteronism: a practical approach to diagnosis and treatment. J Clin Hypertens. 2001;3:189-195.
6. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens. 2006;8:887-893.
7. Kater CE, Biglieri EG, Schambelan M, Arteaga E. Studies of impaired aldosterobe response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism. Hypertens. 1983;5(suppl V):v-115-v-121.
8. Karagiannis A, Tziomalos K, Papageorggiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509-515.
9. Young WF, Hogan MJ, Klee GG, et al. Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc. 1990;65:96-110.
10. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Int Med. 1999;131:105-108.
11. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-825.
12. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921-1926.
13. Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary hyperaldosteronism. Arch Surg. 1996;131:646-650.
14. Brown JJ, Davies DL, Feriss JB, et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ. 1972;2:729-734.
15. Ganguly A, Luetscher JA. Spironolactone therapy in primary aldosteronism: diagnostic and therapeutic implication. In: Sambhi MP, ed. Systemic Effects of Antihypertensive Agents. New York, NY: Stratton Intercontinental Medical Book; 1976:383-392.
16. Born-Frontsberg E, Reincke M, Rump LC, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's registry. J Clin Endocrinol Metab. 2009;94:1125-1130.
17. The Endocrine Society's Clinical Guidelines. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab. 2008;93:3266-3281.
18. Doi SAR, Al-Qudhaiby MM, Al-Humood K, et al. Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension. J Hum Hypertens. 2006;20:482-489.